What Xiamen Spacegen.Co.,Ltd does

Xiamen Spacegen.Co.,Ltd is a privately held Chinese molecular diagnostics company founded in 2015 and headquartered in Xiamen, Fujian, China. The company develops, manufactures, and markets diagnostic test kits for targeted therapies in oncology, with a core technology stack spanning Next-Generation Sequencing (NGS), Real-Time PCR, and Digital PCR for gene mutation detection. Its portfolio is anchored by two patented proprietary technologies: RingCap® (Ring-Link Capture Library technology), which enables a 2-step NGS library preparation in 3.5 hours with 2 working days from sampling to reporting and compatibility with Illumina NextSeq 500/MiniSeq/MiSeq and Ion Torrent PGM S5/Proton sequencers; and PAP-ARMS (Pyrophosphorolysis-Activated Polymerization Amplification Refractory Mutation System), a multiplex fluorescence PCR technique validated on common qPCR machines, designed to avoid cross-contamination and achieve high-sensitivity mutation detection (e.g., 0.2% for ESR1).

The company operates from a ~5,000 sqm footprint comprising 3,500 sqm of GMP-certified production areas, 2,000 sqm of R&D/QC laboratories, and 1,500 sqm of office space. Two wholly-owned subsidiary laboratories — Xiamen SpaceSeq MedLab and Suzhou SpaceSeq MedLab — hold medical institution practice licenses and operate at P2+ biosafety standard, supporting both internal R&D and external clinical testing services. Spacegen generates revenue through two streams: (1) sales of molecular diagnostic kits (NGS, Real-Time PCR, Digital PCR gene mutation detection kits) and (2) laboratory testing services delivered through its subsidiary lab network. The go-to-market is sales-led and direct, targeting healthcare institutions, hospitals, and clinical laboratories in oncology, with channel presence at industry events such as CACLP and active B2B engagement via LinkedIn.

In 2026 the company launched the Breast Cancer ESR1 Gene Mutation Detection Kit (11 mutations, 0.2% sensitivity), presented ctHPV MRD testing at ASCO 2026 for cervical carcinoma monitoring, and obtained full marks in two NCCL External Quality Assessment programs. The company is privately held with no disclosed institutional investors or funding rounds, and employs between 201 and 500 people per its LinkedIn company page (though firmographic metadata lists 10 employees), with all operations currently concentrated in China.

Name

Xiamen Spacegen.Co.,Ltd

Legal name

Xiamen Spacegen.Co.,Ltd

Website

https://sspacegen.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Xiamen Spacegen.Co.,Ltd is a privately held Chinese molecular diagnostics company that develops and markets NGS, Real-Time PCR, and Digital PCR gene mutation detection kits for oncology targeted therapies, serving healthcare institutions in China through direct sales, GMP-certified manufacturing, and two wholly-owned subsidiary clinical labs.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Molecular diagnostics
• Oncology genetic testing
• NGS library preparation
• PCR mutation detection
• Targeted therapy diagnostics

Headquarters

HQ city

Xiamen

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Molecular Diagnostic Kits: Development, manufacture and marketing of diagnostic tests for targeted therapies in oncology including NGS kits, Real-Time PCR kits, and Digital PCR gene mutation detection kits for cancer screening, drug selection, and efficacy monitoring.
2. Laboratory Testing Services: Medical laboratory services provided through subsidiary laboratories (Xiamen SpaceSeq MedLab and Suzhou SpaceSeq MedLab) with medical institution practice license operating at P2+ biosafety standard.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Xiamen Spacegen develops, manufactures, and markets molecular diagnostic kits for targeted cancer therapies using NGS, Real-Time PCR, and Digital PCR technologies. Its portfolio covers gene mutation detection kits for oncology drug selection, early screening, and efficacy monitoring, supported by two wholly-owned P2+ certified clinical laboratories (Xiamen SpaceSeq MedLab and Suzhou SpaceSeq MedLab) that provide medical testing services. Key proprietary platforms include the patented RingCap® library preparation technology and the PAP-ARMS multiplex fluorescence PCR mutation detection system.

Product overview

Xiamen Spacegen.Co.,Ltd is a molecular diagnostics company specializing in the development, manufacture, and marketing of diagnostic tests for targeted therapies in oncology. The company offers a comprehensive portfolio of patented technologies including RingCap (Ring-Link Capture Library) for simplified NGS library preparation and PAP-ARMS for high-sensitivity mutation detection. Their product portfolio comprises NGS gene mutation detection kits, real-time PCR detection kits, digital PCR detection kits, and specialized testing services such as the Breast Cancer ESR1 Gene Mutation Detection Kit and ctHPV MRD testing for cervical cancer. SpaceGen operates subsidiary laboratories (Xiamen SpaceSeq MedLab and Suzhou SpaceSeq MedLab) with P2+ standard certification for clinical testing services. The company focuses on early targeted screening, drug selection, and efficacy monitoring for cancer precision medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• RingCap® NGS Library Preparation Reagent Kits Proprietary RingCap® (Ring-Link Capture Library) library preparation reagent kits for NGS workflows, enabling simplified 2-step library prep in 3.5 hours for clinical and research customers performing targeted gene sequencing.
• PAP-ARMS Gene Mutation Detection Kits Multiplex fluorescence PCR reagent kits based on the patented PAP-ARMS technology for high-sensitivity gene mutation detection, sold to clinical laboratories running qPCR workflows.
• Breast Cancer ESR1 Gene Mutation Detection Kit Detects 11 ESR1 gene mutations (D538G, Y537S, E380Q) in blood samples from breast cancer patients at 0.2% sensitivity, supporting endocrine therapy resistance assessment and targeted therapy selection.
• NGS Gene Mutation Detection Kits Next-generation sequencing reagent kits for detecting cancer gene mutations in targeted therapies, supporting early targeted screening, drug selection, and efficacy monitoring.
• Real-Time PCR Detection Kits Real-time PCR gene mutation detection reagent kits used for early cancer screening and targeted therapy treatment selection.
• Digital PCR Detection Kits Digital PCR-based nucleic acid detection reagent kits for highly sensitive quantification of cancer gene mutations in clinical diagnostics.
• ctHPV MRD Testing Service Non-invasive blood-based ctHPV DNA testing service that provides real-time, quantitative minimal residual disease (MRD) monitoring for cervical carcinoma patients.
• MRD (Minimal Residual Disease) Testing Service Comprehensive MRD monitoring service providing clinicians with precise tumor monitoring data and supporting precision medicine research in oncology.
• Nucleic Acid Mass Spectrometry Products Mass spectrometry-based nucleic acid analysis products used for biomarker detection in molecular diagnostics applications.
• Clinical Laboratory Testing Services (Xiamen SpaceSeq MedLab) Clinical molecular diagnostic testing services provided by Xiamen SpaceSeq MedLab Co., Ltd, a wholly-owned subsidiary laboratory in Xiamen holding a medical institution practice license and operating at P2+ biosafety standard.
• Clinical Laboratory Testing Services (Suzhou SpaceSeq MedLab) Clinical molecular diagnostic testing services provided by Suzhou SpaceSeq MedLab Co., Ltd, a wholly-owned subsidiary laboratory in Suzhou holding a medical institution practice license and operating at P2+ biosafety standard.

Quantifiable outcome

• Library preparation takes only 3.5 hours, with 2 working days from sampling to reporting
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability4 records

Feature2 records

Partnerships

One partnership is on record.

• Xiamen SpaceSeq MedLab Co., LtdcoreOthersWholly-owned subsidiary laboratory operating with medical institution practice license at P2+ biosafety standard. Provides laboratory testing services as part of Spacegen's integrated diagnostic offerings.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Amoy Diagnostics: Amoy Diagnostics is a leading Chinese molecular diagnostics company focused on oncology companion diagnostics using PCR and NGS, headquartered in Xiamen. It is the most direct competitor to Spacegen in oncology mutation detection kits for targeted therapy selection in the same geographic market.
• 3D Medicines: 3D Medicines is a Chinese precision oncology company providing NGS-based companion diagnostics and tumor profiling services. It competes with Spacegen in cancer gene mutation detection kits and lab testing services for hospitals and oncologists in China.
• Burning Rock Biotech: Burning Rock is a China-based oncology NGS company offering both testing services and companion diagnostic kits for cancer therapy selection and MRD monitoring. Comparable to Spacegen on the oncology NGS service-plus-kit model and direct overlap in the same hospital channels.
• Novogene: Novogene is a leading Chinese NGS service provider with strong oncology sequencing offerings and proprietary library prep and bioinformatics capabilities. It competes with Spacegen in clinical NGS services and offers comparable multi-platform sequencing support.

Emerging players

• Singlera Genomics: Singlera Genomics is a Chinese liquid biopsy and cancer diagnostics company focused on ctDNA-based MRD and early detection. It overlaps with Spacegen's ctHPV MRD and oncology liquid biopsy directions in the same Chinese precision medicine market.
• Yikon Genomics: Yikon Genomics is a Chinese molecular diagnostics company offering kits and services in reproductive genetics and oncology. It is comparable to Spacegen as a smaller Chinese IVD player with proprietary PCR/NGS technologies targeting hospital labs.

Broad incumbents

• QIAGEN: QIAGEN is a global molecular diagnostics and sample technologies provider offering PCR and NGS kits and bioinformatics for oncology and infectious disease. Comparable to Spacegen as a global IVD reagent incumbent with multi-platform PCR/NGS solutions and broad hospital lab reach.
• BGI Genomics: BGI Genomics is a dominant Chinese genomics and molecular diagnostics provider offering NGS-based oncology testing, reproductive health, and infectious disease products. It is a broad incumbent whose oncology division directly overlaps with Spacegen's NGS kit and lab testing business.
• Foundation Medicine: Foundation Medicine (a Roche company) is a leading US-based oncology molecular profiling and companion diagnostics provider. Comparable to Spacegen on comprehensive genomic profiling for oncology therapy selection, though operating at much larger scale and primarily US market.
• Guardant Health: Guardant Health is a US liquid biopsy leader offering NGS-based oncology testing including MRD monitoring via Guardant Reveal. Comparable to Spacegen on the MRD and liquid biopsy oncology testing axis, with global scale and reimbursement depth.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/xiamenspacegen

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xiamen Spacegen.Co.,Ltd